[A20-57] Ribociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to commission A20-21
Last updated 20.08.2020
Commission awarded on 06.07.2020 by the Federal Joint Committee (G-BA).
|Initial endocrine therapy in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer|
|Conclusion of dossier assessment A20-21 unchanged: added benefit still not proven.|
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.